The US Supreme Court recently upheld a critical provision of the Inflation Reduction Act, rejecting appeals from major pharmaceutical companies contesting Medicare’s drug price negotiations. This decision leaves several lower court rulings intact, which assert the legality of a program aimed at reducing drug costs for the federal government and taxpayers.
Background on the Medicare Drug Pricing Program
The Inflation Reduction Act, enacted in 2022, allows Medicare to negotiate prices for certain drugs—a significant shift after years of debate. With rising prescription drug costs straining Medicare, this program aims to ease financial pressure on both the government and beneficiaries.
Details of the Supreme Court’s Decision
- The Supreme Court’s decision was made without an accompanying explanation.
- Drug manufacturers, including AstraZeneca and Janssen, claim the negotiations amount to “sham negotiation,” infringing on their rights.
- Lower courts ruled that the companies could choose not to participate in Medicare, thereby affirming the program’s legality.
Financial Implications
In 2021, the federal government allocated over $250 billion to drugs covered by Medicare. The first set of negotiations, involving ten popular medications, is expected to generate $6 billion in savings for the government and reduce out-of-pocket expenses for seniors by $1.5 billion.
Drugs Involved in the Negotiations
- Farxiga (AstraZeneca) – Used for diabetes, heart disease, and kidney disease.
- Eliquis (Bristol Myers Squibb) – A blood thinner for preventing clots and strokes.
AstraZeneca reported a 68% discount on Farxiga’s list price through the negotiated process.
Looking Ahead: Future Negotiations
The second negotiation round, covering 15 drugs, is predicted to save Medicare about $12 billion, with a projected reduction of $685 million in beneficiaries’ out-of-pocket costs when the new prices take effect next January. Ongoing negotiations for a third round are also in progress.
Legal Challenges from Drugmakers
Pharmaceutical companies have mounted numerous legal challenges against the Medicare pricing program. Their arguments suggest violations of the Fifth Amendment, stating that the program forces them to provide drugs without proper compensation. Despite their claims, lower courts consistently ruled against the drugmakers, stating participation in the program is voluntary.
Conclusion
The Supreme Court’s rejection of the pharmaceutical companies’ appeals signifies a pivotal moment in health care policy, reinforcing Medicare’s ability to negotiate drug prices. As legal battles continue, the program is set to affect millions of Americans relying on affordable medication.
